Calyxo

High-Level Overview

Calyxo, Inc. is a commercial-stage medical device company developing innovative solutions for kidney stone treatment. Founded in 2016 and headquartered in Pleasanton, California, it focuses on the CVAC System, the world's first all-in-one device enabling the SURE (Steerable Ureteroscopic Renal Evacuation) procedure—a minimally invasive approach combining laser lithotripsy, irrigation, and vacuum aspiration for complete stone clearance.[1][3][7] This addresses kidney stones, a painful condition consuming significant healthcare resources, serving urologists and patients by improving safety, efficiency, and outcomes.[1][3] Recent growth includes treating over 20,000 patients, launching a second-generation CVAC System with Reverse Deflection for enhanced control, and presenting breakthrough two-year ASPIRE data at WCET 2025.[2][4]

Origin Story

Calyxo was founded in February 2016 to tackle the unmet need for better kidney stone treatments, a common issue burdening healthcare systems.[1][3] Leadership includes CEO Joe Catanese III, PhD, a co-founder of NeoTract (inventor of the UroLift System for BPH, acquired for $1.1B by Teleflex), with a PhD in Bioengineering from UC Berkeley/UC San Francisco.[5] CFO Doug Hughes brings experience from four medtech exits, including NeoTract, while SVP of R&D Ryan Connolly has 23 years in device development.[5] Backed by investors like Questa Capital (founded by Ryan Drant, ex-NEA partner with $1B+ in healthcare deployments), the team leveraged urology expertise for early commercialization.[1][6] Pivotal traction came from launching the CVAC System, rapid adoption, and milestones like 20,000 patients treated by October 2025.[2]

Core Differentiators

• All-in-One CVAC System: Combines laser lithotripsy, irrigation, and vacuum aspiration in one device for the SURE procedure, enabling routine one-time stone removal—unlike fragmented traditional methods.[3][4][7]
• Technological Innovations: Second-generation features Reverse Deflection for intuitive steering and control, improving endourologist access during procedures.[4]
• Proven Clinical Outcomes: Two-year ASPIRE data and 15 WCET 2025 presentations (12 abstracts, 3 videos) demonstrate consistent stone clearance, positioning SURE as a potential standard of care; endorsed by physicians like Dr. Michael McDonald ("game changer") and Dr. Stuart Wolf.[2][4][7]
• Team and Culture: Executives with medtech exits and urology track records; "F.I.T to WIN" values (Find Joy, Integrity, Transparency, Win as a Team) foster collaboration.[1][5]

Role in the Broader Tech Landscape

Calyxo rides the endourology wave, targeting kidney stone disease amid rising demand for minimally invasive devices that reduce retreatment rates and healthcare costs.[1][3][4] Timing aligns with fluid aspiration market growth and evidence-based shifts from legacy ureteroscopy, as CVAC's data proves superior evacuation and outcomes.[2][4] Favorable forces include urologist adoption (20,000+ patients in ~15 months post-launch) and investor interest in commercial medtech, evidenced by pre-IPO shares via EquityZen and Questa backing.[2][6] It influences the ecosystem by accelerating innovation—e.g., Reverse Deflection unlocks broader use—and generating multicenter research that could standardize SURE, easing physician burden and improving patient peace of mind.[3][4]

Quick Take & Future Outlook

Calyxo's momentum—20,000 patients, product iterations, and robust data—positions it for expansion, potentially via FDA clearances, international launches, or acquisition by medtech giants eyeing urology.[2][4] Trends like AI-assisted imaging and value-based care will amplify CVAC's efficiency edge, while endourology conferences signal growing consensus on SURE.[4] Influence may evolve from disruptor to market leader, reimagining stone care as Calyxo delivers on its vision of one-time treatments, building on a foundation of proven innovation and team excellence.[1][3][7]